Abstract: The present invention provides micelles having a polynucleotide encapsulated therein, the micelle comprising copolymers comprising hydrophobic moieties in a cationic complexing block. The invention further provides methods of preparing and using said micelles, and compositions thereof.

Abstract: Aerosol odor eliminating compositions are described which are aqueous based and include at least one alkylene glycol, at least one surfactant wherein one or more of the at least one surfactant has an HLB of about 7 to about 20, compressed gas propellant, at least one fragrance, a buffering system and water. The composition excludes inclusion of a low molecular weight monohydric. The compositions have a volatile organic content (VOC) of less than 5.0% of the total composition based on 100 wt. %, or alternatively, a VOC of less than 0.1% as to the total composition based on 100 wt. % in absence of the wt. % of the active fragrant material of the fragrance. The compositions additionally have a consistent spray rate at multiple pressure ranges.

Abstract: Described herein is the synthesis of adhesive complex coacervates and their use thereof. The adhesive complex coacervates are composed of a mixture of one or more polycations and one or more polyanions. The polycations and polyanions in the adhesive complex coacervate are crosslinked with one another by covalent bonds upon curing. The adhesive complex coacervates have several desirable features when compared to conventional bioadhesives, which are effective in water-based applications. The adhesive complex coacervates described herein exhibit good interfacial tension in water when applied to a substrate (i.e., they spread over the interface rather than being beaded up). Additionally, the ability of the complex coacervate to crosslink intermolecularly increases the cohesive strength of the adhesive complex coacervate. The adhesive complex coacervates have numerous biological applications as bioadhesives and drug delivery devices.

Abstract: An adhesive patch has a support and an adhesive layer formed on at least one surface of the support. The adhesive patch has a peripheral part and a central part 21. The adhesive layer has voids localized in the peripheral part, with the adhesive layer in the central part being substantially free of voids. The peripheral part preferably contains voids at 2.0-100 voids/mm3 on average. Since time-course changes of adhesive layer components such as additives are reduced, the adhesive patch is highly resistant to detachment from the skin, the components do not easily protrude from the edge of the adhesive patch during preservation in a package, adhesion to the inner surface of the package is suppressed, the adhesive patch can be easily removed from the package and edge lifting by cold flow is suppressed during adhesion to the skin.

Abstract: Medical articles having a body member including natural biodegradable polysaccharides are described. The body member is formed from a plurality of natural biodegradable polysaccharides having pendent coupling groups. The body member can also include a bioactive agent which can be released to provide a therapeutic effect to a patient.

Abstract: Biodegradable coatings that include natural biodegradable polysaccharides are described. The coating is formed from a plurality of natural biodegradable polysaccharides having pendent coupling groups.

Abstract: The invention provides active agents, such as paclitaxel, rapamycin, or 17-AAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) (“PEG-b-PLA”) micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-AAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO, which are used in currently known compositions. Additionally, PEG-b-PLA micelles are easier to handle than DMSO and they do not possess a foul odor, which is a problem with formulations currently in clinical trials. Accordingly, the invention provides stable and biocompatible drug formulations that improve bioavailabilty without causing toxicity. It was also found that larger doses of individual drugs in micelle formulations can be administered compared to non-micelle formulations.

Abstract: A kit for promoting hair growth on areas of the scalp that has been affected by fungal infections. The kit reduces the loss of hair, gradually destroys the cause of the loss of hair, and eventually restores the normal hair growth in the areas of the scalp affected by the fungi. The kit is comprised of a first powdered mixture and three liquid compositions. The elements of the kit are applied to the scalp of an individual experiencing hair loss due to fungi.

Abstract: The present invention is directed to a series of sorbitol esters that have two different molecular weight ester chains, one solid and one liquid, which when combined into a single molecule make a polymer that is solid, but has very unique flow properties. These materials find applications as additives to formulations in personal care products where there is a desire to have a structured film (provided by the solid fatty group) and flow properties, (provided by the liquid fatty group). These compounds by virtue of their unique structure provide outstanding skin feel.

Abstract: A composition is disclosed which provides relief from menstrual cramps and muscle cramps within three to seven minutes after ingestion. The composition is preferably a mixture in the form of an aqueous solution with components mixed within approximately fifty percent of the following amounts: 60 mg/liter of calcium gluconate, 75 mg/liter of potassium bicarbonate, 90 mg/liter of L glutamine, 5 mg/liter of calcium chloride, 150 mg/liter of potassium chloride; 60 mg/liter of calcium ascorbate; 100 mg/liter of magnesium glycinate, and 15 mg/liter of potassium citrate. The liquid solution is taken by a human in a dosage of one to four ounces, depending upon the body weight of the person, whether the person is experiencing menstrual cramps or muscle cramps, and the area affected when the person is seeking relief from muscle cramps.

Abstract: A formulation or preparation for treating and preventing arterial and venous thrombi is provided. This preparation includes a non-metal containing photodynamic dye and a fat soluble vitamin. A method of administration for treatment and prophylaxis of arterial and venous thrombi is also provided. This method includes steps of: combining a non-metal containing photodynamic dye and a fat soluble vitamin; combining the non-metal containing photodynamic dye and fat soluble vitamin with a sodium solution; and administering the combination of non-metal containing photodynamic dye, fat soluble vitamin, and sodium solution as an intravenous drip.